RNS Number : 5370O
Goldman Sachs & Co. LLC
12 January 2026
 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

GOLDMAN SACHS & CO. LLC

Company dealt in

AVADEL PHARMACEUTICALS PLC

Class of relevant security to which the dealings being disclosed relate (Note1)

USD 0.01 ordinary shares

Date of dealing

09 January 2026

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

Long

Short


Number

(%)

Number

(%)

(1) Relevant securities

659,345

(0.67)

479,911

(0.49)

(2) Derivatives (other than options)

39,256

(0.04)

47,084

(0.04)

(3) Options and agreements to purchase/sell

0

(0.00)

0

(0.00)

Total

698,601

(0.71)

526,995

(0.54)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

Class of relevant security:

Long

Short


Number

(%)

Number

(%)

(1) Relevant securities





(2) Derivatives (other than options)





(3) Options and agreements to purchase/sell





Total





 

3.    DEALINGS (Note 3)

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit  (Note 4)

Purchase

5

21.4900 USD

Purchase

6

21.4950 USD

Purchase

100

21.4950 USD

Purchase

100

21.4950 USD

Purchase

100

21.5000 USD

Purchase

40

21.5000 USD

Purchase

17

21.5000 USD

Purchase

100

21.5000 USD

Purchase

177

21.5000 USD

Purchase

4

21.5000 USD

Purchase

2

21.5000 USD

Purchase

18

21.5000 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4700 USD

Sale

1

21.4750 USD

Sale

1

21.4750 USD

Sale

1

21.4750 USD

Sale

1

21.4750 USD

Sale

1

21.4750 USD

Sale

1

21.4750 USD

Sale

1

21.4800 USD

Sale

1

21.4800 USD

Sale

1

21.4800 USD

Sale

1

21.4800 USD

Sale

1

21.4800 USD

Sale

2

21.4800 USD

Sale

2

21.4800 USD

Sale

1

21.4850 USD

Sale

1

21.4850 USD

Sale

1

21.4850 USD

Sale

1

21.4850 USD

Sale

1

21.4850 USD

Sale

1

21.4850 USD

Sale

1

21.4950 USD

Sale

1

21.5200 USD

Sale (Borrow Partial Return)

11,000

N/A

Purchase (Loan Partial Return)

536

N/A

 

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD

Nature of transaction  (Note 5)

Number of relevant securities  (Note 6)

Price per unit  (Note 4)





 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option

Writing, selling,  purchasing, varying etc.

Number of securities to which the option relates  (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit  (Note 4)








 

(ii)            Exercising

 

Product name,e.g. call option

Number of securities

Exercise price per unit  (Note 4)




 

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

 

Nature of transaction  (Note 7)

Details

Price per unit (if applicable)  (Note 4)




 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

NONE

 

Is a Supplemental Form 8 attached? (Note 9)        YES

 

Date of disclosure

12 January 2026

Contact name

Papa Lette and Andrzej Szyszka

Telephone number

+33(1) 4212 1459 / +48(22) 317 4817

Name of offeree/offeror with which connected

AVADEL PHARMACEUTICALS PLC

Nature of connection (Note 9)

Advisor to Offeree

 

SUPPLEMENTAL FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

OPEN POSITIONS (Note 1)

 

Product name,e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Swap

Sold

84

0.0000

N/A

13/03/2026

Swap

Purchased

33,762

0.0000

N/A

20/01/2026

 

Notes

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPSFFFFEEMSEDF